Translational Immunogenomics Lab (TIGL)

Overview of Services

The Translational Immunogenomics Laboratory (TIGL) was established to assist investigators at Dana-Farber Cancer Institute (DFCI) and its partners in advancing cancer immunotherapy research through state-of-the-art systems for molecular and cellular analysis of immune response to cancer therapeutics.

 

TIGL evaluates the latest developments in the field, implements the optimal protocol, and invents methods when current approaches are inadequate. We use genomics (often at the single-cell level), proteomics, molecular immunology, and computational methods to study antigen-specific interactions and their involvement in pathways underling anti-tumor immunity.


Our experienced personnel are committed to discovering and exploring essential and translational approaches in immune-oncology and offers technical support and scientific advice to investigators at DFCI and its partners who are interested in studying the immune response to cancer therapeutics.

Staff Contacts

Name Role Phone Email Location
Kenneth Livak Technology Lead Scientist 617-582-9694 KennethJ_Livak@DFCI.HARVARD.EDU Longwood Center 4315J
Shuqiang Li Senior Scientist 617-582-9664 shuqiang@broadinstitute.org Longwood Center 4315H
McKayla Van Orden Research Technician 617-582-9664 mckayla_vanorden@dfci.harvard.edu  
Derin Keskin Immunology Lead Scientist   Derin_Keskin@dfci.harvard.edu Longwood Center 4315J
Kristie Defalco Financial Manager    Kristie_Defalco@dfci.harvard.edu  
         
         

Contacts

Name Role Phone Email Location
Elizabeth Witten
Research Project Manager
 
617-504-2812
 
elizabeth_witten@dfci.harvard.edu
 
Dana 539